Brief: Gain Therapeutics Completes Target Enrollment in Phase 1b GT-02287 Study for Parkinson’s with or without GBA1 Mutation
30/06/2025 21:16
June 30 (Reuters) - Gain Therapeutics Inc GANX.O: GAIN THERAPEUTICS ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 1B CLINICAL STUDY EVALUATING GT-02287 IN PEOPLE WITH PARKINSON’S DISEASE WITH OR WITHOUT A GBA1 MUTATION GAIN THERAPEUTICS INC - BIOMARKER ANALYSIS EXPECTED IN 4Q 2025, EARLIER THAN PLANNED GAIN THERAPEUTICS INC - EXTENDS SCREENING FOR PHASE 1B TRIAL THROUGH JULY 31, 2025 Source text: ID:nGNX1l2PVy Further company coverage: GANX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall